PART I . Rezolute, Inc. (Rezolute, the Company, we or us) is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Summary of Clinical Assets Ersodetug Our lead clinical asset, ersodetug, is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor i...
Q2 FY2026 — expected 2026-09-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-09-17 | 2025-06-30 | 0001104659-25-090848 | EDGAR | 42K words |
| 2024-09-19 | 2024-06-30 | 0001558370-24-012901 | EDGAR | — |
| 2023-09-14 | 2023-06-30 | 0001558370-23-015755 | EDGAR | — |
| 2022-09-15 | 2022-06-30 | 0001558370-22-014432 | EDGAR | — |
| 2021-09-15 | 2021-06-30 | 0001104659-21-115980 | EDGAR | — |
| 2020-10-13 | 2020-06-30 | 0001104659-20-114497 | EDGAR | — |
| 2019-09-10 | 2019-06-30 | 0001144204-19-043983 | EDGAR | — |
| 2018-10-15 | 2018-06-30 | 0001144204-18-053849 | EDGAR | — |
| 2017-09-22 | 2017-06-30 | 0001144204-17-049237 | EDGAR | — |
| 2016-09-28 | 2016-06-30 | 0001144204-16-125780 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-12 | 2025-12-31 | 0001104659-26-014334 | EDGAR | 23K words |
| 2025-11-06 | 2025-09-30 | 0001104659-25-107781 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0001558370-25-007582 | EDGAR | — |
| 2025-02-12 | 2024-12-31 | 0001558370-25-000867 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001558370-24-014893 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001558370-24-008294 | EDGAR | — |
| 2024-02-13 | 2023-12-31 | 0001558370-24-001069 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001558370-23-018839 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001558370-23-009405 | EDGAR | — |
| 2023-02-10 | 2022-12-31 | 0001558370-23-001120 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001558370-22-017176 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001558370-22-008563 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-24 | 0001104659-26-033592 | EDGAR | 1K words |
| 2026-02-12 | 0001104659-26-014287 | EDGAR | — |
| 2026-01-07 | 0001104659-26-001556 | EDGAR | — |
| 2025-11-21 | 0001104659-25-115050 | EDGAR | — |
| 2025-11-12 | 0001104659-25-109559 | EDGAR | — |
| 2025-11-06 | 0001104659-25-107743 | EDGAR | — |
| 2025-10-21 | 0001104659-25-101282 | EDGAR | — |
| 2025-09-17 | 0001104659-25-090834 | EDGAR | — |
| 2025-09-02 | 0001104659-25-085892 | EDGAR | — |
| 2025-08-20 | 0001104659-25-080473 | EDGAR | — |
293 total filings indexed. 261 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001509261 |
| Ticker | RZLT |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
| Website | https://www.rezolutebio.com |
| Listed | 2011-12-23 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report